Work

Successful fatherhood of males with tyrosine kinase inhibitor-resistant chronic myeloid leukemia taking olverembatinib

Year: 2025

Type: article

Abstract: As life expectancy in patients with chronic myeloid leukemia (CML) approaches that of the general population, fertility preservation has become a critical quality-of-life consideration, especially for younger patients. Although third-generation (3G) tyrosine kinase inhibitors (TKIs), such as olverembatinib, demonstrate potent efficacy against TKI-resistant disease, their reproductive safety profiles remain largely undefined. We report two TKI-resistant male patients who achieved sustained deep molecular responses with olverembatinib and who subsequently conceived healthy offspring with their partners. These cases provide clinical evidence that olverembatinib exposure does not preclude normal male fertility or healthy offspring, emphasizing the need for systematic reproductive safety data on 3G TKIs.

Source: Annals of Hematology

DOI: 10.1007/s00277-025-06722-2

Authors: Lu Yu, Qian Jiang

Institutions: Peking University, Peking University People's Hospital

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,590